Thrombotic thrombocytopenic purpura epidemiology and demographics

Jump to navigation Jump to search

Thrombotic thrombocytopenic purpura Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombotic thrombocytopenic purpura from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Peripheral Smear

Direct Coombs Test

von Willebrand Factor-cleaving Protease Activity

X-ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombotic thrombocytopenic purpura epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombotic thrombocytopenic purpura epidemiology and demographics

CDC on Thrombotic thrombocytopenic purpura epidemiology and demographics

Thrombotic thrombocytopenic purpura epidemiology and demographics in the news

Blogs on Thrombotic thrombocytopenic purpura epidemiology and demographics

Directions to Hospitals Treating Thrombotic thrombocytopenic purpura

Risk calculators and risk factors for Thrombotic thrombocytopenic purpura epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

The most proportion of TTP cases occurred after 40 years, black race and femal sex. Congenital forms occur in children.

Epidemiology and Demographics

Incidence

  • The incidence of acuired TTP is about 0.3 per 100,000 adult per year.[1]
  • Data suggests the increased risk of TTP in black race and femal sex.[2]

Prevalence

  • The incidence of TTP is approximately [number range] per 100,000 individuals worldwide.[3]
  • In 2005, the prevalence of TTP was estimated to be 3 cases per 1000,000 individuals worldwide.[4]

Age

  • Patients of all age groups may developTTP.
  • The incidence of TTP increases with age; the median age at diagnosis is 40 years. TTP often occurs after 40 years.

Race

  • TTP usually affects individuals of the black race.[5][6]

Gender

  • Females are more commonly affected by TTP than men. The females to men ratio is approximately 2 to 1.[5][7]

Region

  • The majority of TTP cases are reported in black african and caribbean people.[8]


References

  1. Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN (October 2013). "Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features". Pediatr Blood Cancer. 60 (10): 1676–82. doi:10.1002/pbc.24612. PMID 23729372.
  2. Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN (November 2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". Am. J. Hematol. 85 (11): 844–7. doi:10.1002/ajh.21833. PMC 3420337. PMID 20799358.
  3. Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JA, George JN (July 2005). "The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency". J. Thromb. Haemost. 3 (7): 1432–6. doi:10.1111/j.1538-7836.2005.01436.x. PMID 15978100.
  4. Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JA, George JN (July 2005). "The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency". J. Thromb. Haemost. 3 (7): 1432–6. doi:10.1111/j.1538-7836.2005.01436.x. PMID 15978100.
  5. 5.0 5.1 Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN (November 2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". Am. J. Hematol. 85 (11): 844–7. doi:10.1002/ajh.21833. PMC 3420337. PMID 20799358.
  6. Martino S, Jamme M, Deligny C, Busson M, Loiseau P, Azoulay E, Galicier L, Pène F, Provôt F, Dossier A, Saheb S, Veyradier A, Coppo P (2016). "Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors". PLoS ONE. 11 (7): e0156679. doi:10.1371/journal.pone.0156679. PMC 4934773. PMID 27383202.
  7. Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN (October 2013). "Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features". Pediatr Blood Cancer. 60 (10): 1676–82. doi:10.1002/pbc.24612. PMID 23729372.
  8. Martino S, Jamme M, Deligny C, Busson M, Loiseau P, Azoulay E, Galicier L, Pène F, Provôt F, Dossier A, Saheb S, Veyradier A, Coppo P (2016). "Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors". PLoS ONE. 11 (7): e0156679. doi:10.1371/journal.pone.0156679. PMC 4934773. PMID 27383202.

Template:WH Template:WS


Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.